Oragenics Licenses Novel Technology for Gene Target Identification with Broad Potential to Generate Products for Human Health and Other Applications.Business Editors/Health/Medical Writers
ALACHUA, Flo.--(BUSINESS WIRE)--March 4, 2004
Company Also Receives Phase I SBIR SBIR Small Business Innovation Research (program/grant)
SBIR Space Based Infra-Red
SBIR Speaker-Boundary Interference
SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) Grant Supporting
Applications of the Technology in Tuberculosis
Oragenics, Inc. (OTC OTC
See over-the-counter market (OTC). :OGEN)(TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension VENTURE:ORA ora (o´rah) pl. o´rae [L.] an edge or margin.
ora serra´ta re´tinae the zigzag margin of the retina of the eye. .U) today announced that it has licensed from iviGene Corporation, also of Alachua, FL, applications of a novel technology that enables the rapid identification of potential therapeutic, vaccine or diagnostic targets implicated im·pli·cate
tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates
1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot.
2. in the onset and progression of disease. Oragenics has gained exclusive worldwide rights to this broad platform technology in the areas of cancer and tuberculosis, as well as agricultural and other non-human uses. In return, iviGene will receive from Oragenics royalties on revenues from any products developed using the technology, including royalties on sublicense fees, milestone payments and future product sales.
The company also announced the receipt of a Phase I SBIR Grant from the National Institute of Allergy and Infections Diseases (NIAID NIAID National Institute of Allergy and Infectious Diseases. ) of the National Institutes of Health (NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. ) supporting development of the technology to identify genes of Mycobacterium tuberculosis that are specifically induced during human infections with that pathogen. The grant, covering the period of March 1, 2004 to August 31, 2004 provides Oragenics with $100,000 in research funding.
"This technology enables the simple, fast identification of novel and potentially important gene targets associated with the natural onset and progression of infections, cancers and other diseases in humans and other living organisms, including plants," said Chuck Soponis, Oragenics' president and chief executive officer. "It offers Oragenics the potential to generate and develop a number of product candidates for future out-licensing to corporate partners, particularly in the area of cancer."
He continued, "Our Replacement Therapy product for preventing tooth decay and probiotic pro·bi·ot·ic
A dietary supplement containing live bacteria or yeast that supplements normal gastrointestinal flora, given especially after depletion of flora caused by infection or ingestion of an antibiotic drug. product for oral health are moving from R&D into clinical development and potential out-licensure. Thus we are ideally situated at this time to bring in new R&D technology to exploit our scientific team's talents. The potential that this target identification platform offers for generating a stream of new product opportunities makes its acquisition a great strategic step for Oragenics."
About the In-licensed Technology
The technology platform licensed by Oragenics represents novel methods of identifying genes that are expressed specifically during disease in affected humans or other living organisms. The basis of this platform is a method developed by iviGene co-founder and Oragenics' founder and chief scientific officer, Jeffrey D. Hillman, DMD (1) (Digital Micromirror Device) See DLP.
(2) (Digital Multi-layer Disk) See high-def DVD formats. , PhD, and University of Florida University of Florida is the third-largest university in the United States, with 50,912 students (as of Fall 2006) and has the eighth-largest budget (nearly $1.9 billion per year). UF is home to 16 colleges and more than 150 research centers and institutes. scientists, called in vivo induced antigen technology (IVIAT IVIAT In Vivo Induced Antigen Technology ). IVIAT can quickly and easily identify in vivo induced genes in human infections without the use of animal models, facilitating the discovery of new targets for the development of vaccines, antimicrobials and diagnostics. Dr. Hillman and his collaborators have further developed methods based on this approach to create Change Mediated Antigen Technology (CMAT CMAT Unité de Chimie des Matériaux Inorganiques et Organiques
CMAT Consequence Management Advisory Team
CMAT Center for Microgravity Automation Technology
CMAT Compatible Materials (list; NASA)
CMAT Custodial Management Association of Texas ). CMAT can be used to identify gene targets associated with the onset and progression of cancerous processes and autoimmune diseases. It can also be used to identify novel genes in plant diseases, including genes expressed by the pathogen when it causes the disease and genes expressed by the plant in response to the disease.
Oragenics, Inc. is an emerging biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. The company's lead product is a novel oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The company is also developing a novel antibiotic with broad-spectrum activity against gram positive bacteria and a probiotic product aimed at maintaining oral health. The company is headquartered in Alachua, Florida. For more information about Oragenics, please consult the company's website at www.oragenics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release includes forward-looking statements which reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions which do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (1) the ability to successfully complete development and commercialization of Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic, and probiotic product for oral health; (2) the ability to obtain substantial additional funding; (3) the ability to develop and commercialize products before competitors; (4) the ability to develop commercial products with the in-licensed technology; and (5) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements. The TSX Venture Exchange TSX Venture Exchange
Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.